

**AHNCI Neurologic Oncology Program Tumor Board**

Friday, January 24, 2020

12:00-1:00 p.m.

Jho Conference Room, 6th Floor, AGH

Join Zoom Meeting

<https://zoom.us/j/519670691>

Meeting ID: 519 670 691

Dial by your location

+1 646 558 8656

**Cases to be discussed**

|  |  |  |  |
| --- | --- | --- | --- |
| **Case** | **De-identified patient** | **Reason** | **Presenter** |
| 1 | CR MRN: 10374702 | GBM | AY |
| 2 | DB MRN: 1892990 | 1. Left frontal atypical meningioma, 2.7 centimeters.  Status post subtotal resection in June of 2017 with Dr. Leonardo.  2.  Recurrent right frontal meningioma status post stereotactic radiotherapy receiving 2750 centigray in June of 2018 with Dr. Karlovits.  3.  New 5 centimeter lesion just anterior to previous left frontal meningioma.   Status post definitive radiation therapy completing treatment June of 201  4. Most recent MRI study January 2020 shows interval growth since previous scans. Concern for progressive disease vs radiation effect. | DM |
| 3 | RA MRN:  697270 | 42 y/o female with Right frontal brain metastasis, consistent with known triple positive Ductal Carcinoma of the left breast, diagnosed 6/3/2019. Presenting to review MRI Brain 1/21/20 | TR |
| 4 | ME MRN:  1155782 | 51 y/o female with Right frontal Anaplastic Oligodendroglioma, WHO Grade II (January 2012) transition to WHO Grade III (April 2017), MIB-1 >23 %. Presenting to review MRI Brain 1/21/20. | TR |
| 5 | GM MRN:  2575699 | 63 y/o male with Left parietooccipital Glioblastoma, WHO Grade IV, MGMT Methylated (80.91), IDH Mutant, diagnosed 6/10/2019. Presenting to review MRI Brain 1/22/20. | TR |
| 6 | PG MRN:  136265 | 79 y/o female with Right parietal Glioblastoma, WHO Grade IV, MGMT Methylated (393.38), IDH Wildtype, diagnosed 3/19/2019. Disease recurrence noted on PET Brain 1/21/20. Presenting to review imaging and discuss future treatment plan. Possibility of Gamma Knife? | TR |
| 7 | JW MRN:  4879692 | 34 y/o male with Right temporal-occipital Oligoastrocytoma, WHO Grade II diagnosed 8/2011 with transformation to Anaplastic Astrocytoma, WHO Grade III, IDH Mutant, MGMT Methylated (32.18), diagnosed 9/2015; recurrence on MRI Brain imaging 8/30/2019. S/p Right Parieto-Occipital craniotomy for debulking of mass on 1/2/2020 by Dr. Yu at AGH. Planning to start treatment locally in Altoona. Presenting to discuss with radiation oncology. | TR |
| 8 | SM MRN:  10980092 | 58 y/o male with Left Frontal Gliosarcoma, WHO grade IV, MGMT unmethylated (0.29) IDH-Wild. Patient admitted multiple times to AGH over the past 3 months. Most current admission for altered LOC. MRI Brain 1/23/20 noted likely progression of disease and new herniation. Patient discharged to nursing facility on hospice. Presenting to review imaging. | TR |
| 9 | MM MRN:  5440065 | 77 y/o female with Right frontal Prior low grade Oligodendroglioma now progressed to diffuse Glioma, WHO GRADE III, MGMT Methylated, IDH Wildtype, diagnosed 2001, with recurrence 2019. Enhancement/possible tumor recurrence noted on MRI Brain 1/20/20. Presenting to review MRI Brain and discuss treatment options. | TR |
| 10 | PP MRN:  10398896 | 65 y/o female with Right temporal lobe Glioblastoma,  IDH1 (-), MGMT methylated per CARIS Genomic Testing, diagnosed 10/2/2017. Currently on Avastin once every 3 weeks. Presenting to review MRI Brain 1/23/20. | TR |
| 11 | PD MRN:  11104 | 76 y/o female withLeft frontal Meningioma, confirmed MRI Brain 6/26/2019. Presenting to review MRI Brain  1/23/20. | TR |
| 12 | LB MRN:  5217971 | 62 y/o female with suspected Lymphoma. Final pathology pending. | TR |

AHN CME Credit

**TEXT 412-301-9919**save this number to your contacts–  
will use this **same** number every week to text your attendance

**Today’s SMS Code: GAMHEN**

You must text within THREE hours of the tumor board. You will receive a text confirming receipt and then an email to complete the evaluation. Once the evaluation is completed credit is registered.

Objectives

Upon completion of this activity, participants will have a better understanding of decision-making for complex neurologic oncology problems and be armed with clinical pathways to improve care.

Accreditation:

Allegheny General Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing education for physicians. Allegheny General Hospital designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure:

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) and the policy of Allegheny General Hospital, presenters must disclose all relevant financial relationships, which in the context of their presentation(s), could be perceived as a real or apparent conflict of interest, (e.g., ownership of stock, honoraria or consulting fees). Any identifiable conflicts will be resolved prior to the activity. Any such relationships will be disclosed to the learner prior to the presentation(s).

Moderators: Tulika Ranjan, MD and Stephen Karlovits, MD